Kurma, Sunstone lead CHF 20m round for Synendos Therapeutics

Kurma, Sunstone lead CHF 20m round for Synendos Therapeutics

Kurma Partners and Sunstone Life Science Ventures have led a CHF 20m series-A funding round for Switzerland-based Synendos Therapeutics, a company that develops therapies for central nervous system (CNS) disorders.

Read Previous

Electra hires Stifel for Hotter Shoes sale

Read Next

Redcentric ends sale process following discussions with Macquarie

Most Popular

We use cookies to offer you a better browsing experience. If you continue to use this site, you consent to our use of cookies.
We use cookies to offer you a better browsing experience. If you continue to use this site, you consent to our use of cookies.